Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia
- 作者: Borovskaya T.1, Kamalova S.1, Grigor’eva V.1, Poluektova M.1, Vychuzhanina A.1, Kuchin A.2, Chukicheva I.2, Buravlev E.2, Fomina T.1, Plotnikov M.1, Goldberg V.3, Dygai A.1
-
隶属关系:
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
- Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
- Research Institute of Oncology, Tomsk National Research Medical Center
- 期: 卷 167, 编号 5 (2019)
- 页面: 606-609
- 栏目: General Pathology and Pathological Physiology
- URL: https://journals.rcsi.science/0007-4888/article/view/241957
- DOI: https://doi.org/10.1007/s10517-019-04580-3
- ID: 241957
如何引用文章
详细
Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology. All examined agents decreased the degree of hyperplasia in acinar epithelium; the greatest efficacy was demonstrated by prostagenin. Moreover, dihydroquercetin and p-thyrozol increased the cross-section area of acinar lumina and prostate volume, which is inadmissible in this pathology. These results suggest that the use of phenolic antioxidants in the therapy of benign prostatic hyperplasia should be strictly controlled.
作者简介
T. Borovskaya
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
编辑信件的主要联系方式.
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
S. Kamalova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
V. Grigor’eva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
M. Poluektova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
A. Vychuzhanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
A. Kuchin
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
俄罗斯联邦, Syktyvkar
I. Chukicheva
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
俄罗斯联邦, Syktyvkar
E. Buravlev
Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences
Email: repropharm@yandex.ru
俄罗斯联邦, Syktyvkar
T. Fomina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
M. Plotnikov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
V. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
A. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: repropharm@yandex.ru
俄罗斯联邦, Tomsk
![](/img/style/loading.gif)